
EIKN
Healthcare · Biotechnology · $324.0M market cap
$5.98-0.06 (-1.0%)Nov 13, 4:26 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +9.9% over 90 days · 30-day revisions 2 up, 1 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | Before the open | -1.74 | -1.59 | +8.6% |
| Aug 13, 2026 | After the close | -1.61 | -1.63 | -1.2% |
| May 11, 2026 | After the close | -1.22 | -2.46 | -101.6% |
| Mar 30, 2026 | Time not confirmed | -17.75 | -26.23 | -47.8% |
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers…